Theravance Biopharma, Inc. (TBPH)
| Market Cap | 865.60M +105.1% |
| Revenue (ttm) | 107.46M +66.9% |
| Net Income | 105.90M |
| EPS | 2.06 |
| Shares Out | 51.49M |
| PE Ratio | 8.16 |
| Forward PE | 6.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 255,575 |
| Open | 16.44 |
| Previous Close | 16.46 |
| Day's Range | 16.38 - 16.95 |
| 52-Week Range | 8.33 - 21.03 |
| Beta | 0.17 |
| Analysts | Buy |
| Price Target | 18.40 (+9.46%) |
| Earnings Date | May 4, 2026 |
About TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. fo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for TBPH stock is "Buy." The 12-month stock price target is $18.4, which is an increase of 9.46% from the latest price.
News
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $TBPH--TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm.
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starti...
Theravance Biopharma Plummets As Phase 3 Study Falls Short
Theravance Biopharma Inc. (NASDAQ: TBPH) shares are tumbling on Tuesday following the company's Phase 3 CYPRESS study did not meet its primary endpoint.
Theravance plans strategic review, including possible sale, after drug trial failure
Theravance Biopharma said on Tuesday it is initiating a strategic review, including a possible sale of the company, after its experimental drug to treat a type of blood pressure disorder failed to...
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
Phase 3 CYPRESS study did not meet the primary endpoint , the OHSA Composite Score, a patient reported outcome (PRO) Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at...
Theravance Biopharma Transcript: KOL Event
Ampreloxetine is positioned to address a significant unmet need in MSA-related NOH, with strong clinical evidence, a robust Phase III program, and a focused commercial strategy. If approved, it could become the first durable, disease-specific therapy, with rapid adoption expected among specialists and payers.
Theravance Biopharma Transcript: Evercore ISI 8th Annual HealthCONx Conference
The business is now focused on maximizing cash flow from Yupelri and advancing ampreloxetine for MSA-related nOH, with a pivotal Phase 3 readout expected in Q1. Strong financials, positive payer feedback, and robust clinical data position the company for potential NDA submission and commercial success.
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:3...
Theravance Biopharma to Participate in Upcoming Investor Conferences
DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Eve...
Theravance Biopharma Earnings Call Transcript: Q3 2025
Q3 2025 saw record YUPELRI sales and profitability, non-GAAP break-even, and a strong cash position. The pivotal CYPRESS trial for ampreloxetine remains on track for a Q1 2026 data readout, with significant near-term milestones expected.
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability Open-label portion of the pivotal Phase 3 CYPRESS...
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System Topline results from the ongoing Phase 3 CYPRESS...
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
DUBLIN , Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, Novemb...
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy
DUBLIN--(BUSINESS WIRE)--Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of “Power in the Periphery,” a new disease education campaign for healthcare professionals (HCPs) to raise...
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had signifi...
Theravance Biopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Strong financials and cash flow support ongoing R&D and commercial activities. Ampreloxetine’s Phase 3 data is expected in Q1, targeting a significant unmet need in MSA with NOH. YUPELRI continues robust growth, with strategic focus on patient persistence and community expansion.
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
DUBLIN , Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C.
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
Topline results anticipated in Q1 2026 and , if successful, planning for expedited NDA submission If approved, ampreloxetine could address a critical unmet need as the first therapy with the potentia...
Theravance Biopharma Earnings Call Transcript: Q2 2025
Second quarter results showed strong YUPELRI sales growth, improved profit margins, and a strengthened balance sheet following the Trelegy royalty sale. CYPRESS Phase III enrollment for ampreloxetine is nearly complete, with top-line data expected in six months.
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year 1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale of ...
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
DUBLIN , July 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2025 financial results and provide a business update after market close on Tuesday, Augu...
Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN , July 23, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30 at 12:00 pm ET (...
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
YUPELRI approved by China's NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive fur...
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 ...
Theravance Biopharma Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
YUPELRI continues to drive growth, especially in hospitals, with improved transition of care and pricing strategies. Ampreloxetine's phase III program for MSA is progressing, drawing strong clinical interest, while financial strength is supported by YUPELRI, Trelegy royalties, and disciplined capital allocation.